Clinical Trial Update: Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update on palivizumab for prevention of severe respiratory syncytial virus infection in high-risk Russian infants, including those born…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia
• Congenital Heart Disease
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: Abbott | Conditions: Respiratory Syncytial Virus Infection, Premature Birth | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2011-07-19